Development of gelatin nanoparticles for positron emission tomography diagnosis in pancreatic cancer
Abstract Pancreatic cancer remains difficult to diagnose using currently available imaging probes. Thus, this study aimed to develop a novel imaging agent for the diagnosis of pancreatic cancer using positron emission tomography (PET). Specifically, this study explores gelatin-based nanoparticles fabricated via radiation-induced crosslinking, as gelatin is known for its ability to produce biocompatible materials. Aqueous gelatin solutions were irradiated with γ-rays to produce nanoparticles with average diameters of 5–20 nm via a radiation crosslinking technique. The gelatin nanoparticles were labeled with 64 Cu, exhibiting negative surface potentials. Furthermore, the nanoparticles were evaluated in vivo by injecting them into pancreatic tumor-bearing mice. Notably, the nanoparticles accumulated in the tumors. Hence, 64 Cu-labeled gelatin nanoparticles show promise as a platform for next-generation PET imaging agents for pancreatic cancer.
Authors
- Atsushi Kimura (ORCID: https://orcid.org/0000-0003-0544-2839)
- Kotaro Oyama (ORCID: https://orcid.org/0000-0003-4090-025X)
- Mitsumasa Taguchi (ORCID: https://orcid.org/0000-0002-5545-4689)
- Yumi Sugo
- Tomoya Koizumi
Institutions
- Gunma University (JP)
- National Institutes for Quantum Science and Technology (JP)
Publication Details
- Journal
- Radiochimica Acta
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1515/ract-2024-0304
- Citations
- 1
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.17